Proton MR spectroscopic imaging of basal ganglia and thalamus in neurofibromatosis type 1: correlation with T2 hyperintensities
- PMID: 20959972
- DOI: 10.1007/s00234-010-0776-4
Proton MR spectroscopic imaging of basal ganglia and thalamus in neurofibromatosis type 1: correlation with T2 hyperintensities
Abstract
Introduction: Neurofibromatosis type 1 (NF1) is frequently associated with hyperintense lesions on T2-weighted images called "unidentified bright objects" (UBO). To better characterize the functional significance of UBO, we investigate the basal ganglia and thalamus using spectroscopic imaging in children with NF1 and compare the results to anomalies observed on T2-weighted images.
Methods: Magnetic resonance (MR) data of 25 children with NF1 were analyzed. On the basis of T2-weighted images analysis, two groups were identified: one with normal MR imaging (UBO- group; n = 10) and one with UBO (UBO+ group; n = 15). Within the UBO+ group, a subpopulation of patients (n = 5) only had lesions of the basal ganglia. We analyzed herein seven regions of interest (ROIs) for each side: caudate nucleus, capsulo-lenticular region, lateral and posterior thalamus, thalamus (lateral and posterior voxels combined), putamen, and striatum. For each ROI, a spectrum of the metabolites and their ratio was obtained.
Results: Patients with abnormalities on T2-weighted images had significantly lower NAA/Cr, NAA/Cho, and NAA/mI ratios in the lateral right thalamus compared with patients with normal T2. These abnormal spectroscopic findings were not observed in capsulo-lenticular regions that had UBO but in the thalamus region that was devoid of UBO.
Conclusion: Multivoxel spectroscopic imaging using short-time echo showed spectroscopic abnormalities in the right thalamus of NF1 patients harboring UBO, which were mainly located in the basal ganglia. This finding could reflect the anatomical and functional interactions of these regions.
Similar articles
-
Is magnetic resonance spectroscopy capable of detecting metabolic abnormalities in neurofibromatosis type 1 that are not revealed in brain parenchyma of normal appearance?Pediatr Neurol. 2015 Mar;52(3):314-9. doi: 10.1016/j.pediatrneurol.2014.11.014. Epub 2014 Dec 1. Pediatr Neurol. 2015. PMID: 25585912
-
Thalamic involvement in neurofibromatosis type 1: evaluation with proton magnetic resonance spectroscopic imaging.Ann Neurol. 2000 Apr;47(4):477-84. Ann Neurol. 2000. PMID: 10762159
-
Serial MR imaging and 1H-MR spectroscopy of unidentified bright objects in a case of neurofibromatosis type 1.Brain Dev. 2005 Dec;27(8):595-7. doi: 10.1016/j.braindev.2005.02.008. Brain Dev. 2005. PMID: 15878248
-
Proton MR spectroscopy in Rett syndrome.Comput Med Imaging Graph. 2002 Jul-Aug;26(4):271-5. doi: 10.1016/s0895-6111(02)00016-2. Comput Med Imaging Graph. 2002. PMID: 12074922 Review.
-
The basal ganglia and apraxia.Brain. 1996 Feb;119 ( Pt 1):319-40. doi: 10.1093/brain/119.1.319. Brain. 1996. PMID: 8624692 Review.
Cited by
-
Using a semi-automated approach to quantify Unidentified Bright Objects in Neurofibromatosis type 1 and linkages to cognitive and academic outcomes.Magn Reson Imaging. 2023 May;98:17-25. doi: 10.1016/j.mri.2022.12.022. Epub 2023 Jan 3. Magn Reson Imaging. 2023. PMID: 36608909 Free PMC article.
-
GABA deficiency in NF1: A multimodal [11C]-flumazenil and spectroscopy study.Neurology. 2016 Aug 30;87(9):897-904. doi: 10.1212/WNL.0000000000003044. Epub 2016 Jul 29. Neurology. 2016. PMID: 27473134 Free PMC article.
-
Can the Cognitive Phenotype in Neurofibromatosis Type 1 (NF1) Be Explained by Neuroimaging? A Review.Front Neurol. 2020 Jan 14;10:1373. doi: 10.3389/fneur.2019.01373. eCollection 2019. Front Neurol. 2020. PMID: 31993017 Free PMC article. Review.
-
Multivariate pattern analysis reveals subtle brain anomalies relevant to the cognitive phenotype in neurofibromatosis type 1.Hum Brain Mapp. 2014 Jan;35(1):89-106. doi: 10.1002/hbm.22161. Epub 2012 Sep 11. Hum Brain Mapp. 2014. PMID: 22965669 Free PMC article.
-
Non-Oncological Neuroradiological Manifestations in NF1 and Their Clinical Implications.Cancers (Basel). 2021 Apr 12;13(8):1831. doi: 10.3390/cancers13081831. Cancers (Basel). 2021. PMID: 33921292 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous